WO2003101489A1 - Composition medicinale utilisee dans le traitement des maladies du tube digestif - Google Patents

Composition medicinale utilisee dans le traitement des maladies du tube digestif Download PDF

Info

Publication number
WO2003101489A1
WO2003101489A1 PCT/JP2003/006845 JP0306845W WO03101489A1 WO 2003101489 A1 WO2003101489 A1 WO 2003101489A1 JP 0306845 W JP0306845 W JP 0306845W WO 03101489 A1 WO03101489 A1 WO 03101489A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
oxazepine
dihydro
pyrrolidine
dibenzo
Prior art date
Application number
PCT/JP2003/006845
Other languages
English (en)
Japanese (ja)
Inventor
Youji Yamada
Kazuyoshi Takahashi
Masaki Hashimoto
Original Assignee
Ajinomoto Co.,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co.,Inc. filed Critical Ajinomoto Co.,Inc.
Priority to AU2003241987A priority Critical patent/AU2003241987A1/en
Publication of WO2003101489A1 publication Critical patent/WO2003101489A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the compound [III] that can be used in the present invention has one or more asymmetric carbon atoms, and may have optical isomers. These optical isomers, arbitrary mixtures or racemates thereof are included in the compounds of the present invention. Among these, it is preferable that the configuration at the 2-position of the pyrrolidine ring or piperidine ring bonded to dihydrodibenzoxoxazepine ⁇ is R-form.
  • aromatic rings G, J, K, ⁇ 3 , A, B, and D are the same as above, represents 1 or 2, and V and V 'are chlorine, bromine, iodine, and tosyloxy. And a leaving group such as a mesyloxy group, and U represents a protecting group for an amino group such as a t-butyloxycarbonyl group, a benzyloxycarbonyl group, and a tosyl group.
  • the compound [V] is reacted in the presence of a base by dropwise addition of Nt-butoxycarbonyl 2-piperidylmethyl tosylate represented by the above general formula [VI I], and the like.
  • compound [XVIII] can be produced by condensing compound [XIX] and compound [XX].
  • the condensation reaction refers to, for example, an amidation reaction using N, N, 1-dicyclohexylcarbodiimide or N-dimethylaminopropyl-1-N'-ethylcarbodiimide, a salt thereof, and the like
  • compound [XIX] Can be selected from known methods such as an acid anhydride method in which is converted to an acid anhydride and then condensation, and a method via an acid chloride or an acid bromide of the compound [XIX].
  • the carrier and diluent include glucose, sucrose, lactose, talc, silica, cellulose, methylcellulose, starch, gelatin, ethylene glycol, polyethylene glycol, glycerin, ethanol, water and oils and fats. Is raised.
  • the following mixture was mixed in a conventional manner, and the mixture was tableted to give tablets containing 50 mg of the active ingredient per tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une composition médicinale contenant l'antagoniste des canaux calciques représenté par la formule (I) ou un analogue de celui-ci. La composition est utilisée dans les traitements des maladies accompagnées d'un changement organique du tube digestif.
PCT/JP2003/006845 2002-05-31 2003-05-30 Composition medicinale utilisee dans le traitement des maladies du tube digestif WO2003101489A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003241987A AU2003241987A1 (en) 2002-05-31 2003-05-30 Medicinal composition for treatment for digestive tract disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-160188 2002-05-31
JP2002160188A JP2005343791A (ja) 2002-05-31 2002-05-31 消化管疾患を治療するための医薬組成物

Publications (1)

Publication Number Publication Date
WO2003101489A1 true WO2003101489A1 (fr) 2003-12-11

Family

ID=29706537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/006845 WO2003101489A1 (fr) 2002-05-31 2003-05-30 Composition medicinale utilisee dans le traitement des maladies du tube digestif

Country Status (3)

Country Link
JP (1) JP2005343791A (fr)
AU (1) AU2003241987A1 (fr)
WO (1) WO2003101489A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404359A1 (fr) * 1989-05-27 1990-12-27 Pfizer Limited Dérivés de dibenzothiazépines utiles comme agents antispasmodiques
EP0889043A1 (fr) * 1996-03-11 1999-01-07 Ajinomoto Co., Inc. DERIVES DE 5,11-DIHYDRODIBENZ b,e] 1,4]OXAZEPINE, ET COMPOSITIONS MEDICAMENTEUSES LES COMPORTANT
EP1020466A1 (fr) * 1997-09-10 2000-07-19 Ajinomoto Co., Inc. DERIVES DE 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE ET COMPOSITIONS MEDICAMENTEUSES LES CONTENANT
WO2001017980A1 (fr) * 1999-09-03 2001-03-15 Ajinomoto Co., Inc. Nouveaux procedes de preparation de derives d'oxazepine
EP1142884A1 (fr) * 1999-01-08 2001-10-10 Ajinomoto Co., Inc. Derives d'oxazepine et medicaments contenant ces derives
WO2002096891A1 (fr) * 2001-05-30 2002-12-05 Ajinomoto Co.,Inc. Derives de dihydrodiaryloxazepine, et medicaments contenant ces derives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404359A1 (fr) * 1989-05-27 1990-12-27 Pfizer Limited Dérivés de dibenzothiazépines utiles comme agents antispasmodiques
EP0889043A1 (fr) * 1996-03-11 1999-01-07 Ajinomoto Co., Inc. DERIVES DE 5,11-DIHYDRODIBENZ b,e] 1,4]OXAZEPINE, ET COMPOSITIONS MEDICAMENTEUSES LES COMPORTANT
EP1020466A1 (fr) * 1997-09-10 2000-07-19 Ajinomoto Co., Inc. DERIVES DE 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE ET COMPOSITIONS MEDICAMENTEUSES LES CONTENANT
EP1142884A1 (fr) * 1999-01-08 2001-10-10 Ajinomoto Co., Inc. Derives d'oxazepine et medicaments contenant ces derives
WO2001017980A1 (fr) * 1999-09-03 2001-03-15 Ajinomoto Co., Inc. Nouveaux procedes de preparation de derives d'oxazepine
WO2002096891A1 (fr) * 2001-05-30 2002-12-05 Ajinomoto Co.,Inc. Derives de dihydrodiaryloxazepine, et medicaments contenant ces derives

Also Published As

Publication number Publication date
JP2005343791A (ja) 2005-12-15
AU2003241987A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
JP4700007B2 (ja) Ｎ−［フェニル（ピロリジン−２−イル）メチル］ベンズアミドおよびｎ−［（アゼパン−２−イル）フェニルメチル］ベンズアミド誘導体、この調製方法および治療法における使用
SK129590A3 (en) 3-substituted pyrolidine derivative, preparation method thereof, intermediate products of this method, pharmaceutical composition containing this derivative
EP0505377A1 (fr) Antagonistes de recepteurs muscariniques.
FI81342C (fi) Foerfarande foer framstaellning av farmaceutiskt vaerdefulla basiskt substituerade tricykliska diazepinoner.
JP3331048B2 (ja) インドール誘導体
FI94246C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bentsatsepiini- ja bentsotiatsepiinijohdannaisten valmistamiseksi
KR100340145B1 (ko) 벤즈아제핀유도체및이의중간체화합물
EP3253761A1 (fr) Dérivés 3,3-difluoro-pipéridine en tant qu'antagonistes des récepteurs nmda nr2b
EP1778641A1 (fr) Antagonistes des recepteurs 5-ht7
JP4618127B2 (ja) １，３−ジヒドロ−２ｈ−インドール−２−オン誘導体
Sleevi et al. Optical isomers of rocastine and close analogs: synthesis and H1 antihistaminic activity of its enantiomers and their structural relationship to the classical antihistamines
HUT58329A (en) Process for producing 5,11-dihydro-dibenzo(b,e)(1,4)-thiazepine derivatives and pharmaceutical compositions containing them
WO2003101983A1 (fr) Derive tetrahydropyrane
FI90662B (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-aminoetanolijohdannaisten valmistamiseksi
AU740878B2 (en) 5,11-dihydrodibenz(b,e)(1,4)oxazepine derivatives and medicinal composition containing the same
WO2003101489A1 (fr) Composition medicinale utilisee dans le traitement des maladies du tube digestif
CN117460729A (zh) 作为西格玛配体的新型（高）哌啶基杂环
US7320973B2 (en) Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same
JP2018531949A (ja) 疼痛に対して活性を有する置換モルホリン誘導体
WO2003101490A1 (fr) Composition de medicament contenant un antagoniste des canaux calciques
US6528504B2 (en) Oxazepine derivatives and medicine containing the same
JP2008525512A (ja) ５−ｈｔ７受容体拮抗薬
JP2023046323A (ja) オキサジアゾール誘導体を含有する医薬組成物
CN115916790A (zh) 作为IAP拮抗剂的吡啶并[2,3-b][1,4]噁嗪或四氢吡啶并[2,3-b][1,4]氧氮杂卓
WO2003106423A1 (fr) Amine cyclique et composition médicinale la contenant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP